Development of an orally bioavailable CDK12/13 degrader and induction of synthetic lethality with AKT pathway inhibition
Yu Chang,Xiaoju Wang,Jianzhang Yang,Jean Ching-Yi Tien,Rahul Mannan,Gabriel Cruz,Yuping Zhang,Josh N Vo,Brian Magnuson,Somnath Mahapatra,Hanbyul Cho,Saravana Mohan Dhanasekaran,Cynthia Wang,Zhen Wang,Licheng Zhou,Kaijie Zhou,Yang Zhou,Pujuan Zhang,Weixue Huang,Lanbo Xiao,Weihuang Raymond Liu,Rudana Hamadeh,Fengyun Su,Rui Wang,Stephanie J Miner,Xuhong Cao,Yunhui Cheng,Rohit Mehra,Ke Ding,Arul M Chinnaiyan
DOI: https://doi.org/10.1016/j.xcrm.2024.101752
2024-10-15
Abstract:Cyclin-dependent kinases 12/13 play pivotal roles in orchestrating transcription elongation, DNA damage response, and maintenance of genomic stability. Biallelic CDK12 loss has been documented in various malignancies. Here, we develop a selective CDK12/13 PROTAC degrader, YJ9069, which effectively inhibits proliferation in subsets of prostate cancer cells preferentially over benign immortalized cells. CDK12/13 degradation rapidly triggers gene-length-dependent transcriptional elongation defects, leading to DNA damage and cell-cycle arrest. In vivo, YJ9069 significantly suppresses prostate tumor growth. Modifications of YJ9069 yielded an orally bioavailable CDK12/13 degrader, YJ1206, which exhibits comparable efficacy with significantly less toxicity. To identify pathways synthetically lethal upon CDK12/13 degradation, phosphorylation pathway arrays were performed using cell lines treated with YJ1206. Interestingly, degradation or genetic knockdown of CDK12/13 led to activation of the AKT pathway. Targeting CDK12/13 for degradation, in conjunction with inhibiting the AKT pathway, resulted in a synthetic lethal effect in preclinical prostate cancer models.